Extracellular targeted protein degrader removes antibodies in first test in humans

IF 12.6 1区医学 Q1 ALLERGY

Allergy Pub Date : 2024-06-18 DOI:10.1038/d41573-024-00103-6

Asher Mullard

引用次数: 0

Abstract

Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.

Abstract Image

查看原文本刊更多论文

在首次人体试验中，细胞外靶向蛋白降解器清除了抗体。

Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平--首次临床验证了小分子细胞外蛋白降解剂的潜力。Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平，首次在临床上展示了小分子细胞外蛋白降解剂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.